

70514/wo



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification n ^o 6 : C07H 19/06, 19/16, A61K 31/70, C07D 239/54, 473/00, A61K 31/505, 31/52		A1	(11) International Publication Number: WO 95/35304
			(43) International Publication Date: 28 December 1995 (28.12.95)
(21) International Application Number: PCT/US95/07896		(74) Agents: RENDA, Barbara, L. et al.; Klauber & Jackson, Continental Plaza, 411 Hackensack Avenue, Hackensack, NJ 07601 (US).	
(22) International Filing Date: 21 June 1995 (21.06.95)			
(30) Priority Data: 08/264,026 22 June 1994 (22.06.94) US		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, IS, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, TM, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): MACRONEX, INC. [US/US]; 120-700 Southcenter Court, Morrisville, NC 27560-9136 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): BENSON, Bradley, J. [US/US]; 3306 Whitfield Road, Chapel Hill, NC 27514 (US). CHEN, Xiannong [CN/US]; 148 Cabin Lane Extension, Athens, GA 30603 (US). CIANCIOLO, George, J. [US/US]; 7704 Amesbury Drive, Chapel Hill, NC 27514 (US). DIAZ, Jose-Luis [ES/US]; 112 Wenonah Way, Durham, NC 27713 (US). ISHAQ, Khalid, S. [US/US]; 105 Hunter Hill Place, Chapel Hill, NC 27514 (US). MORRIS-NATSCHKE, Susan, L. [US/US]; 1226 Martha's Chapel Road, Apex, NC 27502 (US). UHING, Ronald, J. [US/US]; 4508 Tyne Drive, Durham, NC 27703 (US). WONG, Henry [US/US]; 106 Ivy Hollow Court, Morrisville, NC 27560 (US).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	


(54) Title: HYDROXYALKYLAMMONIUM-PYRIMIDINES OR PURINES AND NUCLEOSIDE DERIVATIVES, USEFUL AS INHIBITORS OF INFLAMMATORY CYTOKINES

(57) Abstract


Novel hydroxyalkylammonium-pyrimidine and nucleoside derivatives (I) have been found to be useful as inhibitors of inflammatory cytokines. They can be used, *inter alia*, in the therapy of septic shock, cachexia, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and AIDS. The compounds are typically prepared by reaction of an iodo substituted nucleoside with the appropriately substituted hydroxyalkylamine, wherein R is a group of formula (a) wherein R₁ is one or two lower alkyl groups with the proviso that when two lower alkyl groups are present, then the nitrogen atom is quaternized; R₂ is hydrogen or an alkanoyl group of 2-20 carbon atoms; n is 2-6; or R is a substituted furanyl group of formula (b) wherein n, R₁ and R₂ are as hereinbefore defined; and the wavy lines indicate either stereochemical configuration; R' and R'' are independently hydrogen, halogen or a lower alkyl, lower alkenyl, lower alkynyl, or aralkyl group; R''' is hydrogen, halogen, alkylthio, amino, acylamino carbamyl or azide; and the pharmaceutically acceptable salts thereof.



(I)



(a)



(b)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**HYDROXYALKYLAMMONIUM-PYRIMIDINES OR PURINES AND
NUCLEOSIDE DERIVATIVES, USEFUL AS INHIBITORS OF
INFLAMMATORY CYTOKINES**

BACKGROUND OF THE INVENTION

5 Tumor necrosis factor alpha (TNF- α), also known as cachectin, is a 17 kDa protein produced by neutrophils, activated lymphocytes, macrophages, NK cells, LAK cells, astrocytes, endothelial cells, smooth muscle cells, and some transformed cells. A large number of studies reveal
10 that TNF- α is produced principally by macrophages and that it may be produced *in vitro* as well as *in vivo*. This cytokine mediates a wide variety of biological activities, including: cytotoxic effects against tumor cells, activation of neutrophils, growth proliferation of
15 normal cells, and immunoinflammatory, immunoregulatory, and antiviral responses. TNF- α also induces the secretion of interleukin-1 (IL-1) and is a primary mediator of inflammation and endotoxin-induced shock. A 26 kDa membrane form of TNF- α has been described on the
20 surface of monocytes and activated T cells. This molecule may be involved in intracellular communication, as well as cytotoxic activity, and is a surface marker for lymphocyte activation. By a variety of techniques TNF has been shown to exist as a trimer in aqueous
25 solutions; only a small fraction of human TNF molecules occur as monomers at physiological ionic pH.

Two distinct TNF- α receptors have been identified: a 75 kDa receptor and a 55 kDa receptor, TNFR- α and TNFR- β respectively. The intracellular domains of the two TNF
30 receptor types are apparently unrelated, suggesting that they employ different signal transduction pathways. While both receptors are capable of binding TNF and activating the transcription factor NF κ B, it appears that the expression of each receptor is independently and

differentially regulated. Human TNF- α will bind to both types of receptors with equal affinity on human cells.

TNF has been found to be an important mediator of the pathophysiological effects of a diverse array of invasive diseases, infections, and inflammatory states. As a consequence of its production (or overproduction) in tissues, and the presence of other cytokines in the cellular environment, TNF may ultimately benefit or injure the host. For instance, when produced acutely and released in large quantities into the circulation during a serious bacterial infection, it triggers a state of shock and tissue injury (septic shock syndrome) that carries an extremely high mortality rate (30 to 90%). Three main lines of evidence indicates that TNF plays a central role in the development of septic shock: (1) administration of the cytokine to mammals induces a state of shock and tissue injury that is nearly indistinguishable from septic shock; (2) inhibiting TNF in septic shock prevents the development of both shock and tissue injury and confers a significant survival advantage; and (3) TNF is produced in animals and humans during experimental and clinical septic shock syndrome.

When produced during chronic disease states, TNF mediates cachexia, a syndrome characterized by anorexia, accelerated catabolism, weight loss, anemia, and depletion of body tissues. Weight loss frequently develops during chronic illness and, if not reversed, may kill the host before the underlying disease can be eradicated. For instance, it is not unusual for the patient afflicted with cancer or AIDS to lose 50% of body weight and to succumb to complications of malnutrition. By contrast to starvation, during which protein-conserving adaptive responses are maximally operative, the cachectic host tends to catabolize body energy stores

in the face of suppressed intake, thus hastening its own demise.

In addition to septic shock and cachexia, TNF has been implicated in the pathophysiology of rheumatoid arthritis (RA), inflammatory bowel disease (IBD), multiple sclerosis (MS) and AIDS and has been suggested to perhaps play a role in the development of Alzheimer's disease (AD) and/or the weight loss associated with AD patients. In rheumatoid arthritis, for instance, there is evidence of macrophage activation with demonstration of increased amounts of two monokines, TNF- α and IL-1, in the serum but even more in the synovial fluid. TNF- α , an inducer of IL-1, is significantly elevated in rheumatoid arthritis but not in reactive arthritis. Moreover, TNF- α levels in RA correlate with the synovial fluid leukocyte count and with the ESR (erythrocyte sedimentation rate). TNF is an important mediator of immunity and inflammation and because of its biologic activities (activation of neutrophils, release of arachidonic acid metabolites from synovial cells, induction of cartilage resorption and inhibition of proteoglycan release in cartilage, induction of macrophage chemotactic activating protein ([MCAP]) is one of the potential mediators in chronic arthritis. Studies have shown that monoclonal antibody to TNF can ameliorate joint disease in murine collagen-induced arthritis. In these studies, anti-TNF administered prior to the onset of disease significantly reduced paw swelling and histological severity of arthritis without reducing the incidence of arthritis or the level of circulating anti-type II collagen IgG. More relevant to human disease was the ability of the antibody to reduce the clinical score, paw swelling, and the histological severity of disease even when injected after the onset of clinical arthritis.

- More recently, 20 patients with active rheumatoid arthritis were treated with 20 mg/kg of chimeric human/mouse monoclonal anti-TNF- α in an open phase I/II trial lasting eight weeks. The treatment was well-
- 5 tolerated and significant improvements were seen in the Ritchie Articular Index, the swollen joint count, and in other major clinical assessments. Significant decreases were seen in serum amyloid A, IL-6 and c-reactive protein.
- 10 Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system (CNS). The majority of infiltrating cells at the site of demyelination are macrophages and T-cells. IL-1 and TNF in the CSF are detected at higher levels and more
- 15 frequently in patients with active multiple sclerosis than in patients with inactive MS or with other neurological diseases. In a study of MS patients, Beck and colleagues found an increase of TNF and interferon production by peripheral blood mononuclear cells two
- 20 weeks prior to disease exacerbation. Experimental allergic encephalomyelitis (EAE) is the best characterized demyelinating disease of the CNS in animals. EAE and MS share many characteristics. Ruddle and colleagues used a monoclonal antibody which
- 25 neutralizes TNF to treat EAE in mice. See Ruddle et al., J. Exp. Med., 1990, 172:1193-1200. The incidence and severity of EAE in the antibody-treated mice were dramatically reduced and the onset of disease was delayed. Moreover, the authors reported that the
- 30 preventive therapy was long-lived, extending through five months of observation.

TNF- α levels were measured in serum samples from 73 HIV-1 seropositive patients and in samples from two control groups. All clinical groups of HIV-1-infected patients,

35 regardless of concurrent illness, had significantly



elevated levels of both types of soluble TNF receptors (sTNFRs) and immunoreactive TNF- α , with the highest concentrations among the AIDS patients. These TNF parameters were significantly correlated with reduced CD4+ lymphocyte counts. The raised levels of immunoreactive TNF and sTNFRs strongly indicate activation of the TNF- α system during HIV-1 infection. Levels increase with disease progression and degree of immunodeficiency. Thalidomide, a selective inhibitor of TNF- α synthesis, has been shown to suppress the activation of latent HIV-1 in a monocytoid (U1) cell line. Associated with HIV-1 inhibition was a reduction in agonist-induced TNF- α protein and mRNA production. The presence of thalidomide was also shown to inhibit the activation of virus in the peripheral blood mononuclear cells of 16 out of 17 patients with advanced HIV-1 infection and AIDS. A recent study used reverse transcriptase-polymerase chain reaction on homogenized brain tissue to correlate the relative expression of mRNA for TNF- α with cognitive impairment and with neuropathologic changes in HIV infected patients. Levels of mRNA for TNF- α from frontal subcortical white matter were significantly greater in patients with HIVD (HIV associated dementia) than in AIDS patients without dementia or in seronegative controls. Elevated levels of mRNA for TNF- α in HIVD indicate that abnormal cytokine expression may contribute to the pathogenesis of HIVD. Pentoxifylline (PTX), a drug known to block TNF- α release, was tested in a phase I/II clinical trial of HIV-seropositive patients either alone or in combination with zidovudine (ZDV). The mean HIV-1 viral load, as measured by a quantitative polymerase chain reaction technique, was 1.9-fold above baseline values after 12 weeks of PTX and ZDV compared with 8-to 9-fold greater levels in patients given either agent alone ($p < 0.05$). TNF- α levels correlated with viral load ($p < 0.0001$) in patients given the combined drug regimen.

Crohn's disease and ulcerative colitis are chronic inflammatory bowel diseases of unknown etiology but there is circumstantial evidence that immune mechanisms play an important role in the pathogenesis of the intestinal lesion and that cytokines produced by lymphoid cells may be critical for the extraintestinal sequelae of the disease. In both Crohn's disease and ulcerative colitis, activation of macrophages seems to be a key feature and increased production of the macrophage-derived cytokines TNF- α , IL-1, and IL-6 have been reported in both diseases. A recent study determined the location and tissue density of cells immunoreactive for TNF- α in intestinal specimens from 24 patients with chronic inflammatory bowel disease (15 with Crohn's, 9 with ulcerative colitis) and 11 controls (14). There was significantly increased density of TNF- α immunoreactive cells in the lamina propria of both ulcerative colitis and Crohn's disease specimens suggesting that this degree of TNF- α production probably contributes significantly to the pathogenesis of both Crohn's disease and ulcerative colitis by impairing the integrity of epithelial and endothelial membranes, increasing inflammatory cell recruitment, and by prothrombotic effects on the vascular endothelium.

25


SUMMARY OF THE INVENTION

The present invention relates to novel hydroxy alkylammonium-pyrimidines or purines and nucleoside derivatives which are particularly useful as inhibitors of inflammatory cytokines such as IL-1b, IL-6, IL-8, TNF α and tissue factor. More particularly, the present invention relates to novel inhibitors of inflammatory cytokines which are compounds of the Formulae I




(I)

wherein R is a group of the formula



- 5 wherein R_1 is one or two lower alkyl groups with the proviso that when two lower alkyl groups are present, then the nitrogen atom is quarternized; R_2 is hydrogen or a saturated or unsaturated alkanoyl group of 2-20 carbon atoms; n is 2-6; or

- 10 R is a substituted furanyl group of the formula



- wherein n, R_1 and R_2 are as hereinbefore defined; and the
 15 wavy lines indicate either stereochemical configuration; R' and R'' are independently hydrogen, halogen or a low r alkyl, lower alkenyl, lower alkynyl, or aralkyl group; R''' is hydrogen, halogen, alkylthio, amino, acylamino carbamyl or azide; and the pharmaceutically acceptable
 20 salts thereof.

It is thus an object of the present invention to provide hydroxyalkylammonium-pyrimidines or purines and nucleosides which, by virtue of their ability to inhibit inflammatory cytokines, are useful as therapeutic agents
 25 for the treatment of invasive diseases, infections and inflammatory states, particularly septic shock, cachexia, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, AIDS and Alzheimer's disease.

It is further an object of the present invention to
 30 provide synth tic procedures for the preparation of the

novel hydroxyalkylammonium-pyrimidines or purines and nucleosides.

It is a still further object of the present invention to provide a method for treating a mammal affected with
5 septic shock, cachexia, rheumatoid arthritis, inflammatory bowel disease or multiple sclerosis which comprises the administration of an agent which is an inhibitor of inflammatory cytokines.

It is thus a further object of the present invention to
10 provide an AIDS therapy which, in addition to decreasing cachexia, decreases viral load, by administration of a hydroxyalkylammonium-pyrimidine or purine or nucleoside which inhibits inflammatory cytokines.


It is a still further object of the present invention to
15 provide a therapeutic agent which inhibits the development of cachexia by inhibiting TNF and other inflammatory cytokines which are mediators of this disease.

Yet another aspect of the present invention provides a
20 pharmaceutical formulation comprising a compound of Formula I, together with one or more pharmaceutically acceptable carriers, excipients or diluents.

DETAILED DESCRIPTION OF THE INVENTION

The compounds of Formula I are pyrimidine or purine and
25 pyrimidine or purine nucleoside derivatives wherein the pyrimidine base portion is derived from thymine or the purine base portion is derived from a 2-substituted or a 2,6-substituted purine base. Where the compound of Formula I contains the substituted furanyl group of the
30 formula

9



5

the compounds are nucleoside derivatives.

In Formula I, the group $-(CH_2)_n$ wherein n is an integer from 2 to 6, represents an alkylene group of 2 to 6 carbon atoms. Representatives of such groups are ethylene, propylene, butylene, pentylene, hexylene, and their corresponding branched chained isomers.

The lower alkyl groups represented by R' , R'' and R_1 in Formula I contain 1 to 6 carbon atoms and are represented by methyl, ethyl, propyl, butyl, pentyl and hexyl. Similarly, the lower alkenyl and lower alkynyl groups contain 1 to 6 carbon atoms and one or more degrees of unsaturation.

The aralkyl groups include phenyl-, optionally substituted by one or more halogen or lower alkyl groups.


The R_2 alkanoyl groups of Formula I include both saturated and unsaturated alkanoyl containing from 2 to 20 carbon atoms, with the saturated alkanoyl groups containing 8 to 16 carbon atoms, i.e., octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl and hexadecanoyl, being preferred.

The halogen substituent may be a fluorine, chlorine, bromine or iodine substituent.

The compounds of Formula I contain asymmetric carbon atoms which give rise to various stereoisomers. The present invention includes the racemic mixtures, as well as the optically pure compounds of Formula I.


Equivalent to the compounds of Formula I for the purposes of this invention are the biocompatible and pharmaceutically acceptable salts thereof. Such salts can be derived from a variety of organic and inorganic acids including, but not limited to, methanesulfonic, hydrochloric, hydrobromic, hydroiodic, toluenesulfuric, sulfuric, maleic, acetic and phosphoric acids. When the nitrogen atom is quaternized, the compounds of Formula I exist in such salt form.

10 The novel pyrimidine or purine compounds of Formula I wherein R is a group of the formula



15 wherein n, R₁, and R₂ are as hereinbefore defined, are prepared as shown in Scheme I below:

Scheme I



wherein n, R₁, R₂, R' and R'' are as hereinbefore defined. (Pyrimidine base exemplified, purine base reaction is identical with the iodoethoxymethyl substituent being attached at N⁹).


In reaction Scheme I, a 1-[(2-iodoethoxy)methyl]pyrimidine of formula II wherein R', R and R'' are as hereinbefore defined, or a 9-[(2-

iodoethoxy)methyl]purine wherein R' and R'' are as hereinbefore defined, is reacted with the appropriately substituted amine of Formula III wherein n , R and R_1 are as hereinbefore defined, to afford the desired pyrimidine of Formula Ia, or the appropriately substituted purine.

The amine of Formula III can be either a secondary amine or a tertiary amine depending upon whether the desired compound of Formula Ia contains one or two R_1 groups.


This reaction is typically conducted in an anhydrous polar solvent, such as acetonitrile. Typical reaction times are 2 to 6 hours, and usually the reaction is conducted at reflux temperature.

In Scheme II, a synthetic process for the nucleoside compounds of Formula I wherein R is a group of the formula



wherein n , R_1 , R_2 , and the wavy lines are as hereinbefore defined, is shown:

Scheme II



wherein R' , R'' , n , R_1 and R_2 are as hereinbefore defined. (Pyrimidine base exemplified, purine base reaction identical with the 5-iodomethylfuranyl group substituent being attached at the N^9).

In reaction Scheme II, a 5-iodomethylfuranylnucleoside of Formula IIb wherein R' and the wavy lines are as hereinbefore defined, is reacted with the appropriately substituted amine of Formula III wherein n, R₁ and R₂ are as hereinbefore defined to afford the desired pyrimidine of Formula Ib, or the appropriately substituted purine.

As in Scheme I, the amine of Formula III utilized in Scheme II can be either a secondary amine or a tertiary amine depending upon whether the desired compound of Formula Ib contains one or two R₁ groups.

This reaction is typically conducted in an anhydrous polar solvent, such as acetonitrile. Typically, the reaction is conducted at reflux temperatures, with typical reaction times being from 4 to 24 hours.

The utility of the compounds of Formula I as inhibitors of inflammatory cytokines can be demonstrated by activity in standardized assays, described below.

Unless otherwise described the medium for human cell culture assays is defined as follows: RPMI-1640 is supplemented with 100U/ml penicillin, 100µg/ml streptomycin, 2 mM L-glutamine; 1 mM Na pyruvate; 1% MEM non-essential amino acids and 25 mM HEPES; (all from GIBCO, Gaithersburg, MD). Complete medium is defined as medium supplemented with 5% pooled, heat-inactivated (56°C, 30 min.) human AB serum (Pel-freeze, Brown Deer, WI).

Inhibition of LPS-stimulated Cytokine Production in Whole Blood:

Citrated venous blood was obtained from phlebotomized normal donors and aliquoted into 1 ml volumes in 1.5 ml Eppendorf microcentrifuge tubes (Brinkman Instruments, Westbury, NY). Test compound was prepared by making a

100 mM stock solution in 100% DMSO with all subsequent 1/10 dilutions also made in 100% DMSO. Test compound (1.0 μ l) or DMSO alone was then added to 1 ml whole blood so that the final DMSO content was 0.1%. The samples
5 were then rotated at 37°C for 1 hour whereupon LPS (*S. typhosa*, SIGMA, St. Louis, MO) was added to the appropriate samples to a final concentration of 10 ng/ml. All samples were rotated at 37°C for an additional 14 hours whereupon plasma was harvested by spinning at high
10 speed in a microcentrifuge for 2-3 minutes. Samples were then diluted to 1/25, 1/100 and 1/250 in PBS and assayed by ELISA (R & D Systems, Minneapolis, MN) for TNF- α , IL-1 β and IL-6, respectively.

Endotoxin Testing:

15 All batches of media and reagents are tested to ensure they are free of endotoxins before they are used. This laboratory uses a kinetic chromogenic procedure (Kinetic QCL; Whittaker Bioproducts) for the determination of endotoxin, performed using the Thermomax Plate reader
20 from Molecular Devices. The plate reader incorporates dedicated software for the computer analysis of all data. Samples are tested following the manufacturer's instructions, at 3 different concentrations, in triplicate. Reference Standard Endotoxin (United States
25 Pharmacopeia) obtained at a concentration of 10,000 endotoxin units/ml, is used to generate a standard curve to determine the actual concentration of endotoxin in the samples (sensitivity = \geq 0.005 endotoxin units/ml).

Human Peripheral Blood Mononuclear Cell (PBMC) Isolation:

30 Venous blood is obtained from healthy volunteers and mixed with an equal volume of sterile isotonic saline/10 mM HEPES and placed into 50 ml conical polypropylene tubes in 30 ml aliquots. Each aliquot of diluted blood

is underlaid with 20-25 ml of sterile Lymphocyte Separation Medium (LSM; Organon-Technika, Durham, NC). The tubes are centrifuged at 400 g for 40 minutes at room temperature. The mononuclear cells at the interface are removed and washed twice in sterile isotonic saline/10 mM HEPES followed by a wash in Hank's Balanced Salt Solution (HBSS) or RPMI without serum, depending on their intended use. Cell concentrations for each donor are determined by counting in a haematology and analyser (Serono-Baker).

10 *PBMC Proliferation to Mitogens (PHA):*

PBMC are adjusted to $4 \times 10^6/\text{ml}$ in complete medium. To each well of a 96 well flat bottom tissue culture plate (Falcon 3072) is added 50 μl of cell suspension. Test materials (diluted in complete medium to 2X the desired final concentration) are added in 100 μl volumes to each well. All samples are tested in quadruplicate at four concentrations (spanning 3 logs₁₀). Control wells receive complete medium alone. Background response wells receive an additional 50 μl of complete medium, while all other wells receive 50 μl mitogen (diluted in complete medium to 4X the desired final concentration). Dexamethasone (50 μl) at a final concentration of 10 nM is included in each assay as an internal standard for inhibition. The mitogens used and their final concentrations are: OKT3 (anti-CD3 antibody; 100ng/ml; Ortho) and PHA (phytohaemagglutinin A; 1.0 $\mu\text{g}/\text{ml}$; Sigma). The plates are then incubated for 3 days at 37°C in humidified 5% CO₂, pulsed for the final 6 hours with 0.5 $\mu\text{Ci}/\text{well}$ of ³H-thymidine (6.7 Ci/mmol; Amersham, Arlington Heights, IL) in 50 μl complete medium. The contents of the wells are harvested onto glass fibre filters using a multiple automated sample harvester (Tomtec), and the incorporated ³H-thymidine determined by liquid scintillation spectrophotometry and represented as cpm (counts per minute) incorporated per well.

Two-Way Mixed Lymphocyte Reaction (MLR):

PBMC are prepared as described for the mitogen assays, but resuspended to 2×10^6 cells/ml in complete medium. Fifty μ l of cell suspension from two different individuals is then added to each well of a 96-well flat bottom tissue culture plate. An additional 100 μ l of complete medium, dexamethasone or test compounds are then added to each well, the plates are incubated for 6 days at 37°C, and then pulsed with ^3H -thymidine and harvested as previously described.

Monocyte Release of Cytokines and Growth Factors:

Monocytes are prepared by centrifugal counterflow elutriation from peripheral blood mononuclear cells obtained from leukaphoresis of normal volunteers (leukopaks) at Duke University, Durham, NC. A panel has been compiled of 24 healthy donors who have been pre-screened and whose peripheral blood mononuclear cells (PBMC) have been found to respond in a normal manner to mitogenic stimulation and stimulation by a specific antigen (tetanus toxoid). Their monocytes have also been found to respond in a normal manner when activated with lipopolysaccharide (LPS) *in vitro*.

Total cells are taken from leukopaks before elutriation and used to carry out *in vitro* assays measuring human PBMC responses to mitogens and antigens, PBMC obtained by separation on a LSM gradient (as described above) are resuspended in PBS and separated, using a Beckman elutriator, into lymphocytes and monocytes. Yields of 10^9 monocytes with greater than 90% purity are routinely obtained.

Purified monocytes prepared as described above are suspended at 4×10^6 cells/ml in complete medium. To each

well of a 48-well flat bottomed tissue culture plate is added 0.125 ml of cell suspension. Test materials (diluted in complete medium at 2X the desired final concentration) are added in 250 μ l volumes to each well.

5 Control wells receive 250 μ l of complete medium or 250 μ l of IL-4 (diluted to X 2 the desired final concentration of 50 ng/ml). All samples are tested at four concentrations in the presence or absence of 100 ng/ml LPS (125 μ l of 4X desired final concentration added) and

10 incubated at 37°C in humidified 5% CO₂, for 16 hours. At this time, culture supernatants are aspirated off, and the unattached cells and cell debris are removed by a 2 minute spin in a microcentrifuge at 10,000 g. The release of cytokines and growth factors is determined in

15 the cell-free supernatants using ELISA capture assays. In this way, testing for IL-1 β , TNF- α , IL-1 receptor antagonist, IL-6, IL-8, GM-CSF and PDGF is conducted.

Monocyte Procoagulant Activity (Tissue Factor):

The adhered monocytes remaining on the 48-well tissue

20 culture plates after removal of the supernatants above, are used to measure levels of Tissue Factor production. The cells are solubilized overnight at 4°C in 10% Triton-X100 in PBS, diluted to 1% Triton-X100 with PBS then assayed by ELISA for Tissue Factor.

25 *Monocyte Release of PGE₂, LTB₄, and PAF:*

Monocytes isolated as described above, were washed and resuspended in RPMI containing 5 mg/ml HSA at 2 X 10⁶ cells/ml and added to wells of a 48-well plates. The cells were allowed to adhere for 2 hours then washed in

30 HBSS-BSA-HEPES buffer. Test materials were added at four concentrations (175 μ l) for 60 minutes; then the monocytes were stimulated by addition of 300 mg/ml zymosan A (175 μ l of 2X desired final concentration

added). Supernatant medium was collected from the wells after 90 minutes incubation and stored at -20°C until assayed. Supernatants were assayed for PGE_2 , LTB_4 or PAF using specific scintillation proximity assays (SPA).

5 Monocyte Superoxide Anion (O_2^-) Release:

Monocytes are prepared as described above and resuspended to $5 \times 10^6/\text{ml}$ in HBSS containing 10 Mm HEPES, 2 g/l glucose, 0.1% BSA, Ph 7.2. To each well of a 96-well flat bottom, tissue culture plate is added 100 μl of cell suspension and 100 μl of buffer or test materials. Samples are run in quadruplicate. The plate is incubated for 60 min. at 37°C followed by the addition of 50 μl of buffer containing cytochrome C (5 mg/ml; type VI, horse heart, Sigma) and bovine liver catalase (1500 U/ml; Sigma) in the presence of zymosan A (PMA; 750 $\mu\text{g}/\text{ml}$; Sigma). The plate is incubated an additional 120 minutes at 37°C during which the absorbance at 550 nm is monitored using a microplate reader incorporating dedicated software for kinetic analysis (Molecular Devices; Menlo Park, CA).

Inhibition of Monocyte Chemotaxis:

Monocytes are prepared as previously described, and resuspended at 5×10^6 cells/ml in HBSS, 0.1% BSA (HBSS-BSA). Fluorophore labeling of the cells is carried out by adding calcein-AM to the above cells at a final concentration of 2 μM . Following a 30 minute incubation at 37°C in humidified 5% CO_2 , the labeled monocytes are washed twice and incubated in a range of dilutions of the test materials for 60 minutes at 37°C in humidified 5% CO_2 . The pre-treated, calcein-AM loaded cells are then added in triplicate to the wells of the top compartment of a NeuroProbe (Cabin, John, M.D.) 96-well chemotaxis chamber (2×10^5 cells/well) and permitted to migrate

through a 10 μ m thick bonded polycarbonate membrane (5 μ m porosity; NeuroProbe Inc; Cabin, John, M.D.) towards the wells of the lower compartment containing the chemoattractant (FMLP) at 5×10^{-9} M. After a 90 minute incubation at 37°C in a humidified chamber, the wells of the upper chambers are aspirated, the monocyte-associated membrane removed, non-migrating cells wiped off and the filters permitted to air dry to 15 minutes. The number of cells migrating through the membranes are quantified by measuring the fluorescent intensity of the migrating cells in a fluorescent microplate reader (CytoFluor 2300, Millipore Corp., Bedford, MA)

Monocyte Adherence to Vascular Endothelial Cells:

Human umbilical vein endothelial cells (HUVEC) are obtained from Clonetics (San Diego, CA). Confluent layers of epithelial cells are prepared by seeding 96-well plates with 2×10^4 cells/well and incubating at 37°C in humidified 5% CO₂ for 24 hours. TNF α (50 μ g) was then added to each well (10 μ l of a 5 ng/ml stock solution) prior to the addition of monocytes. Monocytes are fluorescently labelled and pre-treated with test materials as described above, resuspended in complete medium to a final concentration of 2×10^6 cells/ml and incubated in triplicate in wells (100 μ l/well) for 60 minutes at 37°C in humidified 5% CO₂. Plates are then sealed and centrifuged at 250 g for 5 minutes to remove non-adhered monocytes and the number of adhered cells determined by reading plates on a fluorescent microplate reader.

When tested in the above standardized assays, a representative compound of Formula I, i.e., N,N-dimethyl-N-2-(hexadecanoyloxy)ethyl-N-[N¹-5-methyl-2,4-dioxypyrimidinyl)methoxyethyl]ammonium iodide was found to give the results shown below in Table 1.

TABLE 1

5	COMPOUND: N,N-dimethyl-N-2-(hexadecanoyloxy) ethyl-N-[N ¹ -5-methyl-2,4-dioxypyrimidinyl] methoxyethyl] ammonium iodide		
10	ASSAY	EFFECT	UNITS: μ m EC ₅₀
	ENDOTOXIN	NE	
	PHA	NE	
	MLR	NE	
15	GM-CSF	INHIB	12.6
	IL1 β	INHIB	7.5
	ILra	NT	
	IL6	INHIB	5.7
	IL8	INHIB	2.9
20	TNF α	INHIB	5.5
	TISSUE FACTOR	INHIB	4.30
	PGE ₂	NE	
	LTB ₄	NE	100.00
	PAF	NE	
25	SUPEROXIDE	INHIB	34
	CHEMOTAXIS	INHIB	47
	MTS	TC	100.00
	LDH	TC	100.00

Key:

30	NE	No effect
	NT	Not tested
	INHIB	Inhibition
	STIM	Stimulation
	IC ₂₀	20% Inhibitory Concentration
35	EC ₅₀	50% Effective Concentration
	TC	Tolerated Concentration

Additionally, the compounds of Formula I exhibit activity as antiherpes, anti-tumor and antiviral agents when tested in standardized assays for such activity.

The ability of the compounds of Formula I to inhibit the action of various inflammatory cytokines make them useful in a wide variety of therapeutic methods. Specifically, their ability to mediate or inhibit the actions of TNF- α makes these compounds useful in the treatment of various invasive diseases, infections, and inflammatory states. Particularly important is the inhibition of the large amount of TNF produced during serious bacterial infections, which can trigger a state of shock and tissue injury (septic shock syndrome).

A further important use of the compounds of Formula I is to inhibit the TNF which is known to mediate cachexia produced during chronic disease states. Thus, these compounds are particularly useful in adjunctive therapy for AIDS and cancer patients to reduce and/or ameliorate the consequences of cachexia produced during these chronic disease states.

A further specific method of treatment for which the compounds of the instant invention are particularly useful is in the treatment of rheumatoid arthritis wherein increased amounts of the inflammatory cytokines, TNF- α and IL-1 are present. By virtue of their ability to mediate and/or inhibit the action of these cytokines, inflammation and the severity of the disease state can be reduced or eliminated.

The compounds of the instant invention can also be utilized in the treatment of multiple sclerosis (MS), Crohn's disease and ulcerative colitis by inhibiting and the activity of the inflammatory cytokines which underlie these disease states.

The compounds of the present invention are likewise useful in the therapeutic methods described in U.S. Patent 5,306,732 by virtue of their ability to act as antagonists of tumor necrosis factor.

- 5 The compounds for use in the methods of the present invention can be, and are preferably, administered as medicaments, i.e., pharmaceutical compositions.

The pharmaceutical compositions used in the methods of this invention for administration to animals and humans
10 comprise the compounds of Formula I in combination with a pharmaceutical carrier or excipient.

The medicament can be in the form of tablets (including lozenges and granules), dragees, capsules, pills, ampoules or suppositories comprising the compound of the
15 invention.

"Medicament" as used herein means physically discrete coherent portions suitable for medical administration.
"Medicament in dosage unit form" as used herein means physically discrete coherent units suitable for medical
20 administration, each containing a daily dose or a multiple (up to four times) or a sub-multiple (down to a fortieth) of a daily dose of the active compound of the invention in association with a carrier and/or enclosed within an envelope. Whether the medicament contains a
25 daily dose or, for example, a half, a third or a quarter of a daily dose will depend on whether the medicament is to be administered once or, for example, twice, three times a day, respectively.

Advantageously, the compositions are formulated as dosage
30 units, each unit being adapted to supply a fixed dose of active ingredients. Tablets, coated tablets, capsules, ampoules and suppositories are examples of preferred

dosage forms according to the invention. It is only necessary that the active ingredient constitute an effective amount, i.e., such that a suitable effective dosage will be consistent with the dosage form employed
5 in single or multiple unit doses. The exact individual dosages, as well as daily dosages, will, of course, be determined according to standard medical principles under the direction of a physician or veterinarian.

The compounds of Formula I can also be administered as
10 suspensions, solutions and emulsions of the active compound in aqueous or non-aqueous diluents, syrups, granulates or powders.

Diluents that can be used in pharmaceutical compositions (e.g., granulates) containing the active compound adapted
15 to be formed into tablets, dragees, capsules and pills include the following: (a) fillers and extenders, e.g., starch, sugars, mannitol and silicic acid; (b) binding agents, e.g., carboxymethyl cellulose and other cellulose derivatives, alginates, gelatine and polyvinyl
20 pyrrolidone; (c) moisturizing agents, e.g., glycerol; (d) disintegrating agents, e.g., agar-agar, calcium carbonate and sodium bicarbonate; (e) agents for retarding dissolution, e.g., paraffin; (f) resorption accelerators, e.g., quaternary ammonium compounds; (g) surface active
25 agents, e.g., cetyl alcohol, glycerol monostearate; (g) adsorptive carriers, e.g., kaolin and bentonite; (i) lubricants, e.g., talc, calcium and magnesium stearate and solid polyethylene glycols.

The tablets, dragees, capsules and pills comprising the
30 active compound can have the customary coatings, envelopes and protective matrices, which may contain opacifiers. They can be so constituted that they release the active ingredient only or preferably in a particular part of the intestinal tract, possibly over a period of

time. The coatings, envelopes and protective matrices may be made, for example, from polymeric substances or waxes.

The compounds of Formula I can also be made up in
5 microencapsulated form together with one or several of the above-mentioned diluents.

The diluents to be used in pharmaceutical compositions adapted to be formed into suppositories can, for example, be the usual water-soluble diluents, such as polyethylene
10 glycols and fats (e.g., cocoa oil and high esters, [e.g., C_{14} -alcohol with C_{16} -fatty acid]) or mixtures of these diluents.

The pharmaceutical compositions which are solutions and emulsions can, for example, contain the customary
15 diluents (with, of course, the above-mentioned exclusion of solvents having a molecular weight below 200, except in the presence of a surface-active agent), such as solvents, dissolving agents and emulsifiers. Specific non-limiting examples of such diluents are water, ethyl
20 alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (for example, ground nut oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of
25 sorbitol or mixtures thereof.

For parental administration, solutions and suspensions should be sterile, e.g., water or arachis oil contained in ampoules and, if appropriate, blood-isotonic.

The pharmaceutical compositions which are suspensions can
30 contain the usual diluents, such as liquid diluents, e.g., water, ethyl alcohol, propylene glycol, surface active agents (e.g., ethoxylated isostearyl alcohols,

polyoxyethylene sorbitols and sorbitan esters), microcrystalline cellulose, aluminum methahydroxide, bentonite, agar-agar and tragacanth, or mixtures thereof.

5 The pharmaceutical compositions can also contain coloring agents and preservatives, as well as perfumes and flavoring additions (e.g., peppermint oil and eucalyptus oil), and sweetening agents, (e.g., saccharin and aspartame).

10 The pharmaceutical compositions will generally contain from 0.5 to 90% of the active ingredient by weight of the total composition.

In addition to the compounds of Formula I, the pharmaceutical compositions and medicaments can also contain other pharmaceutically active compounds.

15 Any diluent in the medicaments of the present invention may be any of those mentioned above in relation to the pharmaceutical compositions. Such medicaments may include solvents of molecular weight less than 200 as the sole diluent.

20 It is envisaged that the compounds of Formula I will be administered perorally, parenterally (for example, intramuscularly, intraperitoneally, subcutaneously, transdermally or intravenously), rectally or locally, preferably orally or parenterally, especially

25 perlingually, or intravenously.

The dosage rate, e.g., 0.05 to 20 mg/kg of body weight, will be a function of the nature and body weight of the human or animal subject to be treated, the individual reaction of this subject to the treatment, type of
30 formulation in which the active ingredient is administered, the mode in which the administration is

carried out and the point in the progress of the disease or interval at which it is to be administered. Thus, it may in some case suffice to use less than a minimum dosage rate, while other cases an upper limit must be exceeded to achieve the desired results. Where larger amounts are administered, it may be advisable to divide these into several individual administrations over the course of the day.

The present invention will be better understood from a consideration of the following examples, which describe the preparation of compounds and compositions illustrative of the present invention. It will be apparent to those skilled in the art that many modifications, both of materials and methods, may be practiced without departing from the purpose and intent of this disclosure.

EXAMPLES

All melting points were taken on a Thomas Hoover melting point apparatus and are uncorrected. Infrared spectra (IR) were recorded on a Perkin-Elmer 1320 spectrophotometer. ¹H NMR spectra were obtained using a Bruker AC-300 NMR. The assignment of complex NMR signals was accomplished by comparison with known standard spectra. The chemical shifts were reported in parts per million relative to an internal standard of tetramethylsilane. Elemental analyses were performed by Atlantic Microlab Inc., Norcross, GA. Due to the hygroscopic nature of some of the quaternary ammonium compounds, their structures were confirmed by high resolution mass spectroscopy by using a VG70-SQ spectrometer. Thin layer chromatography (TLC) was performed on 1x3 inch fluorescent precoated Whatman Silica Gel 60Å TLC plates. The TLC plates were visualized by UV light, iodine vapor, or charring

following sulfuric acid spray. Silica gel (70-230 mesh) from Fisher Scientific was used for column chromatography. Reagents were purchased from Aldrich. Solvents, including acetonitrile, N,N-dimethylformamide (DMF), methylene chloride, and tetrahydrofuran (THF), were dried by placement over molecular sieves (4 Å) for 2 weeks before use.

EXAMPLE A

2-Acetoxyethyl acetoxymethyl ether:

- 10 A mixture of dioxolane (35 mL, 0.5 mol) and acetic anhydride (42.5 mL, 0.5 mol) was cooled in ice to 0°C. Concentrated H₂SO₄ (0.3 mL, 0.005 mol) was added dropwise with stirring. Gas evolution occurred immediately, and the temperature rose slightly. The reaction mixture was
- 15 allowed to warm to room temperature and stirred overnight. The reaction mixture was then poured into saturated ice-cold NaHCO₃ solution (200 mL) and extracted with CHCl₃ (150 mL). The chloroform layer was washed with saturated NaHCO₃ and dried over anhydrous Na₂SO₄.
- 20 The drying agent was suction filtered, and evaporation of chloroform yielded a liquid, which was distilled under vacuum at 0.9 mmHg. After the removal of a small amount of low boiling material, the product was obtained at 46°C at 0.9 mmHg (lit. bp 120-130°C at 30 mmHg). Yield 58%;
- 25 Wt. 51.5 g; IR (neat) 2950 (aliphatic CH) and 1730 (CO ester) cm⁻¹; ¹H NMR (CDCl₃) 1.9-2.1 (s, CH3CO), 3.6-3.8 (t, COOCH2 CH2O), 4.0-4.2 (t, CO O CH2CH2O), 5.1-5.3 (s, OCH O). The product was used in the next example without further purification.

30

EXAMPLE B

1-[(2-Acetoxyethoxy)methyl] thymine:

Thymine (0.63 g, 5 mmol) was added to 2-acetoxyethyl acetoxymethyl ether (1.32 g, 7.5 mmol) dissolved in

2 (15 mL). The reaction mixture was stirred at room temperature and N,O-bis(trimethylsilyl)acetamide (2.96 mL, 12 mmol) was added dropwise. After 3 hours of stirring, the clear solution was cooled to 0°C, and SnCl₄ (0.12 mL, 1 mmol) was added. The reaction mixture was allowed to come to room temperature and stirred overnight. A mixture of saturated aqueous NaHCO₃ (25 mL) and CHCl₃ (50 mL) was prepared and cooled in ice. The reaction mixture was added slowly with vigorous stirring; a white foam formed immediately. After filtration, the aqueous layer was further extracted with ethyl acetate (3x 25 mL) and CHCl₃ (25 mL), and the combined organic layers were dried over anhydrous Na₂SO₄. After filtration of drying agent and removal of solvents in vacuo, an oily liquid was obtained. It was purified on a silica gel column using 2:1 CHCl₃/CH₃COCH₃ as the eluent to give the desired product. Yield 36%; Wt. 4.0 g; mp 105-107 °C; ¹H NMR (DMSO-d₆) 1.8 (s, CH₃ C5 thymine), 2.0 (s, CH₃ CO), 3.65 (m, CO O CH₂ CH₂), 4.1 (m, CO O CH₂ CH₂), 5.05 (s, O CH₂ N), 7.55 (s, H C6 thymine), 11.3 (s, HN thymine).

EXAMPLE C

1-[(2-Hydroxyethoxy)methyl] thymine:

To a solution of 1-[(2-acetoxyethoxy)methyl] thymine (4 g, 16 mmol) in CH₃OH (100 mL) was added NaOCH₃ in CH₃OH (20 mL, 1N). After 2 hours of stirring at room temperature, 1N HCl was added to adjust the pH to 4.0. Methanol and water were removed under vacuum to obtain a solid. The solid was dissolved in CH₃OH and crystallized by dropwise addition of CHCl₃; it was used in the next reaction without further purification. Yield 76%; Wt. 2.5 g; mp 154-156°C; ¹H NMR (DMSO-d₆) 1.75 (s, CH₃ C5 thymine), 3.55-3.75 (A2B2 pattern, O CH₂ CH₂ O), 5.10 (s, O CH₂ N), 7.55 (s, H C6 thymine), 11.3 (s, HN thymine).

EXAMPLE D

1-[(2-Iodoethoxy)methyl] thymine:

Methyltriphenoxyphosphonium iodide (10 g, 24 mmol) was added in five aliquots to a solution of 1-[(2-hydroxyethoxy)methyl] thymine (2.5 g, 12 mmol) in dry DMF (70 mL). The reaction mixture was stirred at room temperature for 20 minutes, then CH₃OH (3 mL) was added to decompose the unreacted methyltriphenoxyphosphonium iodide. After 20 minutes, DMF was removed under high vacuum, and the residue was dissolved in CHCl₃ (50 mL). The chloroform solution was washed with sodium thiosulfate (2x25 mL, 1N) and water (2x25 mL), then dried over anhydrous Na₂SO₄. After filtration of drying agent and removal of CHCl₃ in vacuo, a slightly yellow oil was obtained. The desired product was obtained through crystallization from chloroform by slow addition of hexane. Yield 80%; Wt. 3.0 g; mp 112-115°C; ¹H NMR (CDCl₃) 1.9 (s, CH₃ C5 thymine), 3.25 (m, I CH₂ CH₂), 3.85 (m, I CH₂ CH₂), 5.20 (s, O CH₂ N), 7.25 (s, H C6 thymine).

EXAMPLE E

5'-Iodothymidine:

Thymidine (0.97 g, 4 mmol) and methyltriphenoxyphosphonium iodide (2.18 g, 4.8 mmol) were dissolved in dry DMF (10 mL). The reaction mixture was stirred at room temperature for 20 minutes. Then methanol (5 mL) was added to decompose excess methyltriphenoxyphosphonium iodide. After stirring another 20 minutes, DMF was removed under high vacuum, and chloroform (30 mL) was added to the residue and stirred. The insoluble solid was filtered. The filtrate (slightly yellow) was washed with sodium thiosulfate (25 mL, 1N) and water (25 mL) and dried over magnesium sulfate. After filtration of drying agent, evaporation

of chloroform gave a solid, which was combined with the solid obtained above and dissolved in CH₃OH. Silica gel chromatography using chloroform/methanol (9:1) yielded 1 g of pure product. Yield 72%; mp 172-175°C; ¹H NMR (pyridine-d₅) 1.95 (s, CH₃ C5 thymine), 2.45-2.65 (m, H₂ C2'), 3.55-3.75 (m, H₂ C5'), 4.20-4.30 (m, H C4'), 4.65-4.75 (m, H C3'), 6.90-7.00 (m, H C1'), 7.65 (s, H C6 thymine).

EXAMPLE F

10 2-Bromoethyl octanoate:

2-Bromoethanol (4 g, 32 mmol) was added dropwise to a solution of octanoyl chloride (7.8 g, 48 mmol) and pyridine (5 mL) in benzene (50 mL). The reaction mixture was stirred at room temperature for 24 hours. After
15 evaporation of benzene and pyridine under high vacuum, the residue was redissolved in benzene (100 mL). The solution was washed with water (50 mL), sulfuric acid solution (3x25 mL, 0.5 N), sodium bicarbonate solution (25 mL, 1N), and water (2x75 mL). The benzene layer was
20 dried over Na₂SO₄. The drying agent was suction filtered, and the benzene was evaporated. The resulting oil was purified by silica gel chromatography using chloroform/methanol (9:1) to give 6.5 g of pure product. Yield 81%; liquid; IR (neat) 2930 and 2850 (aliphatic
25 CH), 1730 (CO ester) cm⁻¹; ¹H NMR (CDCl₃) 0.85-0.95 (t, CH₃ (CH₂)₄), 1.20-1.40 (m, CH₃ (CH₂)₄), 1.55-1.70 (m, CH₂ CH₂ CO), 2.25-2.40 (t, CH₂ CH₂ CO), 3.50-3.60 (t, O CH₂ CH₂ Br), 4.35-4.40 (t, O CH₂ CH₂ Br).

EXAMPLE G

30 2-Bromo thyl hexadecanoate:

This intermediate was prepared in a manner analogous to that of 2-bromoethyl octanoate from 2-bromoethanol (4 g, 32 mmol), hexadecanoyl chloride (13.2 g, 48 mmol), and

pyridine (5 mL) in benzene (50 mL). Silica gel chromatography using chloroform/methanol (9:1) yielded 9.75 g pure product. Yield 84%; liquid; ^1H NMR (CDCl_3) 0.85-0.95 (t, CH_3 (CH_2)₁₂), 1.20-1.40 (m, CH_3 (CH_2)₁₂),
5 1.55-1.70 (m, CH_2 CH_2 CO), 2.25-2.40 (t, CH_2 CH_2 CO),
3.50-3.60 (t, O CH_2 CH_2 Br), 4.35-4.40 (t, O CH_2 CH_2 Br).

EXAMPLE H

3-Bromopropyl hexadecanoate:

This intermediate was prepared in a manner analogous to
10 that of 2-bromoethyl octanoate from 3-bromo-1-propanol
(2.53 g, 18 mmol), hexadecanoyl chloride (6.25 g, 22.5
mmol), and pyridine (4 mL) in benzene (50 mL). Silica
gel chromatography using chloroform/methanol (9:1)
yielded 5.7 g pure product. Yield 69%; liquid; ^1H NMR
15 (CDCl_3) 0.85-0.95 (t, CH_3 (CH_2)₁₂); 1.20-1.40 (m, CH_3
(CH_2)₁₂), 1.55-1.70 (m, CH_2 CH_2 CO), 2.13-2.23 (m, O CH_2
 CH_2 CH_2 Br), 2.28-2.38 (t, CH_2 CH_2 CO), 3.45-3.50 (t, O
 CH_2 CH_2 CH_2 Br), 4.35-4.40 (t, O CH_2 CH_2 CH_2 Br).

EXAMPLE I

20 2-(Dimethylamino)ethyl octanoate:

2-Bromoethyl octanoate (0.2 g, 0.72 mmol) and 40% aqueous
dimethylamine (4.2 mL, 36 mmol) were dissolved in
acetonitrile (10 mL). The reaction mixture was stirred
at room temperature for 48 hours. After removal of
25 acetonitrile under vacuum, chloroform (30 mL) was added.
The chloroform layer was extracted with potassium
carbonate solution (20 mL, 0.01N) and water (2x20 mL),
then was dried over sodium sulfate. The drying agent was
suction filtered, and the chloroform removed in vacuo.
30 The resulting material was applied to a silica gel column
(discontinuous gradient of chloroform/methanol 95:5, 8:2
as eluent) affording 0.13 g pure product. Yield 77%;
liquid; ^1H NMR (CDCl_3) 0.85-0.95 (t, CH_3 (CH_2)₄), 1.20-

1.40 (m, CH₃ (CH₂)₄), 1.55-1.70 (m, CH₂ CH₂ CO), 2.25-2.40 (t, CH₂ CH₂ CO), 2.45-2.55 (s, (CH₃)₂ N) 2.75-2.85 (t, O CH₂ CH₂ N), 4.25-4.35 (t, O CH₂ CH₂ N).

EXAMPLE J

5 2-(Dimethylamino)ethyl hexadecanoate:

This intermediate was prepared in a manner analogous to that of 2-(dimethylamino)ethyl octanoate from 2-bromoethyl hexadecanoate (0.2 g, 0.55 mmol) and 40% aqueous dimethylamine (3.5 mL, 27.5 mmol) in acetonitrile
10 (10 mL). The resulting product was applied to a silica gel column (discontinuous gradient of chloroform/methanol 95:5, 8:2 as eluent) affording 0.13 g pure product. Yield 72%; mp 46-48 °C; ¹H NMR (CDCl₃) 0.85-0.95 (t, CH₃ (CH₂)₁₂), 1.20-1.40 (m, CH₃ (CH₂)₁₂), 1.55-1.70 (m, CH₂ CH₂ CO), 2.25-2.40 (t, CH₂ CH₂ CO); 2.45-2.55 (s, (CH₃)₂ N) 2.75-2.85 (t, O CH₂ CH₂ N), 4.25-4.35 (t, O CH₂ CH₂ N).
15 N).

EXAMPLE K

20 3-(Dimethylamino)propyl hexadecanoate:

This intermediate was prepared in a manner analogous to that of 2-(dimethylamino)ethyl octanoate from 3-bromopropyl hexadecanoate (3 g, 7.95 mmol) and 40% aqueous dimethylamine (15 mL, 119 mmol) in acetonitrile (20 mL). The resulting material was applied to a silica
25 gel column (discontinuous gradient of chloroform/methanol 95:5, 8:2 as eluent) affording 1.3 g pure product. Yield 72%; mp 49-50°C; ¹H NMR (CDCl₃) 0.85-0.95 (t, CH₃ (CH₂)₁₂), 1.20-1.40 (m, CH₃ (CH₂)₁₂), 1.55-1.70 (m, CH₂ CH₂ CO), 1.88-2.00 (m, O CH₂ CH₂ CH₂ N), 2.27-2.35 (t, CH₂ CH₂ CO), 2.37-2.45 (s, (CH₃)₂ N) 2.50-2.62 (t, O CH₂ CH₂ CH₂ N), 4.10-4.18 (t, O CH₂ CH₂ CH₂ N).
30

EXAMPLE 1

N,N-Dimethyl-N-2-hydroxyethyl-N- [N¹- (5-methyl-2,4-dioxypyrimidinyl)methoxyethyl] ammonium iodide:
1-[(2-Iodoethoxy)methyl] thymine (100 mg, 0.32 mmol) and
5 2-dimethylaminoethanol (34.5 mg, 0.38 mmol) were dissolved in acetonitrile (10 mL). The reaction mixture was heated to a gentle reflux and stirred for 5 hours. After cooling to room temperature, 77 mg of pure product was obtained through crystallization by slow addition of
10 ethyl ether. Yield 59%; mp 158-161°C; ¹H NMR (CD₃CN) 1.85-1.88 (s, CH₃ C5 thymine), 3.10-3.15 (s, (CH₃)₂ N), 3.30 (s, HO CH₂), 3.45-3.48 (m, N CH₂ CH₂ O), 3.55-3.58 (m, HO CH₂ CH₂ N), 3.90-4.00 (m, HO CH₂ CH₂ N CH₂ CH₂ O), 5.10 (s, O CH₂ N), 7.30 (s, H C6 thymine). Elemental
15 Analysis (C₁₂H₂₂N₃O₄I); Calcd. C, 36.10%; H, 5.56%; N, 10.53%; Found C, 36.17%; H, 5.57%; N, 10.43%

EXAMPLE 2

N,N-Dimethyl-N-3-hydroxypropyl-N- [N¹- (5-methyl-2,4-dioxypyrimidinyl)methoxyethyl] ammonium iodide:
20 The title compound was synthesized in a manner analogous to that of the compound of Example 1 from 1-[(2-iodoethoxy)methyl] thymine (100 mg, 0.32 mmol) and 3-dimethylamino-1-propanol (40 mg, 0.38 mmol) in acetonitrile (10 mL). Yield 59%; mp 178-180°C; ¹H NMR
25 (DMSO-d₆) 1.75-1.80 (s, CH₃ C5 thymine), 1.75-1.90 (m, HO CH₂ CH₂ CH₂ N), 3.05-3.15 (s, (CH₃)₂ N), 3.40-3.50 (m, HO CH₂ CH₂ CH₂ N), 3.50-3.60 (m, N CH₂ CH₂ O), 3.85-3.95 (m, HO CH₂ CH₂ CH₂ N CH₂ CH₂ O), 4.75-4.85 (t, HO CH₂), 5.05-5.10 (s, O CH₂ N), 7.55-7.60 (s, H C6 thymine), 11.35-
30 11.40 (s, HN thymine). Elemental Analysis (C₁₃H₂₄N₃O₄I); Calcd. C, 37.78%; H, 5.85%; N, 10.17%; Found C, 37.73%; H, 5.83%; N, 10.09%.

EXAMPLE 3

N,N-Dimethyl-N-2,3-dihydroxypropyl-N- [N¹-(5-methyl-2,4-dioxypyrimidinyl)methoxyethyl] ammonium iodide:

The title compound was synthesized in a manner similar to
5 that of the compound of Example 1 from 1-[(2-iodoethoxy)methyl] thymine (100 mg, 0.32 mmol) and 3-dimethylamino-1,2-propandiol (46 mg, 0.38 mmol) in acetonitrile (10 mL). Yield 55%; mp 163-165°C; ¹H NMR (DMSO-d₆) 1.75-1.80 (s, CH₃ C5 thymine), 3.10-3.15 (s,
10 (CH₃)₂ N), 3.60-3.70 (m, CH₂ N CH₂), 3.80-4.10 (m, HO CH₂ CH(OH) CH₂ N CH₂ CH₂ O), 4.95-5.00 (t, HO CH₂), 5.05-5.10 (s, O CH₂ N), 5.20-5.25 (d, HO CH₂ CH(OH) CH₂), 7.55-7.60 (s, H C6 thymine), 11.35-11.40 (s, HN thymine).
Elemental Analysis (C₁₃H₂₄N₃O₅I); Calcd. C, 36.37%; H, 5.64%; N, 9.79%; Found C, 36.46%; H, 5.67%; N, 9.78%

EXAMPLE 4

N-Methyl-N-2-hydroxyethyl-N- [N¹-(5-methyl-2,4-dioxypyridinyl)methoxyethyl] amine:

1-[(2-Iodoethoxy)methyl] thymine (200 mg, 0.65 mmol) and
20 2-(methylamino)ethanol (242 mg, 3.3 mmol) were dissolved in acetonitrile (8 mL). The reaction mixture was heated to a gentle reflux and stirred for 5 hours. After evaporation of acetonitrile, chloroform (50 mL) was added, and the solution was washed with sodium hydroxide
25 solution (20 mL, 1N) and water (2x20 mL). The chloroform layer was then dried over anhydrous sodium sulfate. The drying agent was suction filtered, and the chloroform removed under vacuum. The resulting residue was purified by column chromatography using a discontinuous
30 chloroform/methanol (9:1, 7:3) gradient to give 95 mg of pure product. Yield 60%; mp 58-60°C; ¹H NMR (CD₃OD) 1.85-1.92 (s, CH₃ C5 thymine), 2.25-2.35 (s, CH₃ N), 2.55-2.60 (t, HO CH₂ CH₂ N CH₂), 2.60-2.65 (t, HO CH₂ CH₂ N CH₂), 3.55-3.70 (m, HO CH₂ CH₂ N CH₂ CH₂ O), 5.10-5.15

(s, O CH2 N), 7.45-7.50 (s, H C6 thymine). Elemental Analysis (C₁₁H₁₉N₃O₄); Calcd. C, 51.35%; H, 7.44%; N, 16.33%; Found C, 51.09%; H, 7.48%; N, 16.12%.

EXAMPLE 5

5 N,N-Dimethyl-N-2-(octanoyloxy)ethyl-N-[N¹-(5-methyl-2,4-dioxypyrimidinyl)methoxyethyl] ammonium iodide:
1-[(2-Iodoethoxy)methyl] thymine (30 mg, 0.097 mmol) and
2-(dimethylamino)ethyl octanoate (100 mg, 3.9 mmol) were
dissolved in acetonitrile (10 mL). The reaction mixture
10 was heated to a gentle reflux and stirred for 24 hours.
After the removal of acetonitrile under vacuum, benzene
(5x20 mL) was added to the residue, and the solution was
decanted to remove the unreacted starting material. Pure
product (40 mg) was obtained by column chromatography
15 (discontinuous gradient of CHCl₃:MeOH 9:1, 7:3). Yield
74%; mp 96-98°C; hygroscopic; ¹H NMR (CDCl₃) 0.80-1.00 (t,
CH3 (CH2)₄), 1.20-1.40 (m, CH₃ (CH2)₄), 1.50-1.70 (m,
CH2 CH2 CO), 1.85-1.95 (s, CH₃ C5 thymine), 2.30-2.45 (m,
CH2 CH2 CO), 3.30-3.60 (s, (CH3)₂ N), 3.90-4.10 (m, CH2 N
20 CH2), 4.15-4.30 (m, CH₂ CH2 O CH₂ N₁), 4.50-4.65 (m,
C(O)O CH2), 5.20-5.35 (s, O CH2 N₁). FAB Mass Spectrum
(M)⁺; Calcd. 398.2654 (C₂₀H₃₆O₅N₃); Found 398.2644
(2.5 ppm).

EXAMPLE 6

25 N,N-Dimethyl-N-2-(hexadecanoyloxy)ethyl-N-[N¹-(5-methyl-2,4-dioxypyrimidinyl)methoxyethyl] ammonium iodide:
The title compound was synthesized in a manner analogous
to the compound of Example 5 from 1-[(2-
iodoethoxy)methyl] thymine (200 mg, 0.65 mmol) and 2-
30 (dimethylamino)ethyl hexadecanoate (600 mg, 2.0 mmol) in
acetonitrile (10 mL). Yield 49%; Wt. 203 mg; mp 144-
146°C; ¹H NMR (CDCl₃) 0.80-1.00 (t, CH3 (CH2)₁₂), 1.20-
1.40 (m, CH₃ (CH2)₁₂), 1.50-1.70 (m, CH2 CH2 CO), 1.85-

35

1.95 (s, CH3 C5 thymine), 2.30-2.45 (m, CH2 CH2 CO),
3.30-3.60 (s, (CH3)2 N), 3.90-4.10 (m, CH2 N CH2), 4.15-
4.30 (m, CH2 CH2 O CH2 N1), 4.50-4.65 (m, C(O)O CH2),
5.20-5.35 (s, O CH2 N1), 7.35-7.40 (s, H C6 thymine),
5 9.95-10.25 (s, HN thymine). Elemental Analysis
(C28H52O5N3I); Calcd. C, 52.74%; H, 8.22%; N, 6.59%
Found C, 52.48%; H, 8.23%; N, 6.45%.

EXAMPLE 7

N,N-Dimethyl-N-3-(hexadecanoyloxy)propyl-N-[N¹-(5-methyl-
10 2,4-dioxypyrimidinyl)methoxyethyl] ammonium iodide:
The title compound was synthesized in a manner analogous
to the compound of Example 5 from 1-[(2-
iodoethoxy)methyl] thymine (200 mg, 0.65 mmol) and 3-
(dimethylamino)propyl hexadecanoate (600 mg, 1.7 mmol) in
15 acetonitrile (10 mL). Yield 29%; Wt. 120 mg; mp 133-
135°C; ¹H NMR (CDCl₃) 0.80-1.00 (t, CH3 (CH2)12), 1.20-
1.40 (m, CH3 (CH2)12), 1.50-1.70 (m, CH2 CH2 CO), 1.85-
1.95 (s, CH3 C5 thymine), 2.15-2.28 (m, O CH2 CH2 CH2 N),
2.30-2.40 (m, CH2 CH2 CO), 3.30-3.50 (s, (CH3)2 N), 3.65-
20 3.72 (m, CH2 N CH2 CH2 O), 3.90-4.03 (m, CH2 N CH2 CH2
O), 4.15-4.35 (m, CH2 CH2 O CH2 N1; C(O)O CH2), 5.20-5.35
(s, O CH2 N1), 7.35-7.40 (s, H C6 thymine), 9.80-9.85 (s,
HN thymine). FAB Mass Spectrum (M)⁺; Calcd. 524.4064
(C29H54O5N3); Found 524.4043 (3.9 ppm).

25

EXAMPLE 8

N,N-Dimethyl-N-2-hydroxyethyl-N-[5'-(2',5'-di-
deoxythymidinyl)] ammonium iodide:
A solution of 5'-iodothymidine (0.5 g, 1.4 mmol) and 2-
dimethylaminoethanol (5 mL, 49 mmol) in DMF (30 mL) was
30 heated to 50°C for 3 hours. After DMF was removed under
high vacuum, chloroform (2x 20 mL) was added to dissolve
the unreacted starting material. After decanting the
chloroform, the residue was purified via column

chromatography (chloroform/methanol discontinuous gradient 6:4 to 3:7) Yield 52%; Wt. 0.32 g; hygroscopic; ¹H NMR (CD₃OD) 1.90-2.00 (s, CH₃ C5 thymine), 2.20-2.35 (m, H C2'), 2.42-2.55 (m, H C2'), 2.85-2.90 (d, HO C3'),
5 3.20-3.35 (s, N (CH₃)₂), 3.55-3.65 (t, HO CH₂ CH₂ N CH₂), 3.85-3.95 (d, HO CH₂ CH₂ N CH₂), 4.00-4.05 (m, HO CH₂), 4.22-4.31 (H C4'), 4.35-4.42 (H C3'), 6.18-6.26 (t, H C1'), 7.50-7.55 (s, H C6 thymine). FAB Mass Spectrum (MH)⁺; Calcd. 314.1716 (C₁₄H₂₄O₅N₃); Found 314.1731 (4.7
10 ppm).

EXAMPLE 9

N-Methyl-N-hydroxyethyl-N-[5'-(2',5'-dideoxy)thymidinyl] amine:

The title compound was synthesized in a manner similar to
15 that of the compound of Example 8 from 5'-iodothymidine (0.2 g, 0.57 mmol) and 2-(methylamino)ethanol (0.21 g, 2.8 mmol, 5 fold excess) in acetonitrile (8 mL). Yield 55%; Wt. 94 mg; hygroscopic; ¹H NMR (CD₃OD) 1.88-1.95 (s, CH₃ C5 thymine), 2.20-2.35 (m, H C2'), 2.48-2.60 (m, H C2'),
20 2.68-2.70 (d, HO C3'), 2.81-2.90 (s, N CH₃), 3.40-3.54 (m, HO CH₂ CH₂ N CH₂), 3.75-3.80 (m, HO CH₂ CH₂ N CH₂), 3.82-3.91 (m, HO CH₂), 4.22-4.31 (H C4'), 4.35-4.42 (H C3'), 6.18-6.26 (t, H C1'), 7.50-7.55 (s, H C6 thymine). FAB Mass Spectrum (MH)⁺; Calcd. 300.1559
25 (C₁₃H₂₂O₅N₃); Found 300.1562 (1.0 ppm).

EXAMPLE 10

N,N-Dimethyl-N-3-hydroxypropyl-N-[5'-(2',5'-dideoxythymidinyl)] ammonium iodide:

The title compound was prepared in a manner analogous to
30 that of the compound of Example 8 from 5'-iodothymidine (0.5 g, 1.4 mmol) and 3-dimethylamino-1-propanol (5.8 mL, 49 mmol) in DMF (30 mL). The compound was purified via column chromatography (discontinuous gradient of

chloroform/methanol 6:4, 3:7). Yield 54%; Wt. 0.35 g; hygroscopic; ¹H NMR (CD₃OD) 1.90-1.95 (s, CH₃ C5 thymine), 1.95-2.10 (HO CH₂ CH₂ CH₂), 2.20-2.35 (m, H C2'), 2.42-2.55 (m, H C2'), 2.85-2.90 (d, HO C3'), 3.00-3.03 (t, HO CH₂), 3.20-3.35 (s, N (CH₃)₂), 3.52-3.62 (m, HO CH₂ CH₂ CH₂ N CH₂), 3.85-3.95 (m, HO CH₂ CH₂ CH₂ N CH₂), 4.00-4.05 (m, HO CH₂), 4.22-4.31 (H C4'), 4.35-4.42 (H C3'), 6.18-6.26 (t, H C1'), 7.50-7.55 (s, H C6 thymine). FAB Mass Spectrum (MH)⁺; Calcd. 328.1872 (C₁₅H₂₆O₅N₃); Found 328.1882 (3.1 ppm).

EXAMPLE 11

N,N-Dimethyl-N-[2-(octanoyloxy)ethyl]-N-[5'-(2',5'-dideoxy)thymidinyl] ammonium iodide:

The title compound was prepared according to the procedure described for the compound of Example 5 from 5'-iodothymidine (0.2 g, 0.57 mmol) and 2-(dimethylamino)ethyl octanoate (1 g, 4.0 mmol) in acetonitrile (10 mL). Yield 36%; Wt. 0.12 g; mp 103-106°C; hygroscopic; ¹H NMR (CDCl₃) 0.70-0.78 (t, CH₃ (CH₂)₄), 1.11-1.23 (m, CH₃ (CH₂)₄), 1.42-1.53 (m, CH₂ CH₂ CO), 1.70-1.75 (s, CH₃ C5 thymine), 2.11-2.23 (m, H C2'), 2.18-2.25 (t, CH₂ CH₂ CO), 2.32-2.45 (m, H C2'), 3.12-3.18 (s, (CH₃)₂ N), 3.22 (s, HO), 3.65-3.72 (m, O' CH₂ CH₂ N CH₂), 3.75-3.82 (m, H C4'), 3.95-4.12 (m, O CH₂ CH₂ N CH₂), 4.29-4.42 (m, H C3'; C(O)O CH₂), 6.02-6.10 (t, H C1'), 7.40-7.43 (s, H C6 thymine). FAB Mass Spectrum (M)⁺; Calcd. 440.2761 (C₂₂H₃₈O₆N₃); Found 440.2759 (0.45 ppm).

EXAMPLE 12

N,N-Dimethyl-N-[2-(hexadecanoyl xy)ethyl]-N-[5'-(2',5'-dideoxy)-thymidinyl] ammonium iodide:

The title compound was prepared in a manner similar to that of the compound of Example 5 from 5'-iodothymidine

(0.2 g, 0.57 mmol) and 2-(dimethylamino)ethyl hexadecanoate (0.6 g, 1.7 mmol) in acetonitrile (10 mL). Yield 30%; Wt. 0.12 g; mp 148-150°C; hygroscopic; ¹H NMR (CDCl₃) 0.70-0.78 (t, CH₃ (CH₂)₁₂), 1.11-1.23 (m, CH₃ (CH₂)₁₂), 1.42-1.53 (m, CH₂ CH₂ CO), 1.70-1.75 (s, CH₃ C5 thymine), 2.11-2.23 (m, H C2'), 2.18-2.25 (t, CH₂ CH₂ CO), 2.32-2.45 (m, H C2'), 3.12-3.18 (s, (CH₃)₂ N), 3.22 (s, HO), 3.65-3.72 (m, O CH₂ CH₂ N CH₂), 3.75-3.82 (m, H C4'), 3.95-4.12 (m, O CH₂ CH₂ N CH₂), 4.29-4.42 (m, H C3'; C(O)O CH₂), 6.02-6.10 (t, H C1'), 7.40-7.43 (s, H C6 thymine). Elemental Analysis (C₃₀H₅₄O₆N₃I); Calcd. C, 53.01%; H, 8.01%; N, 6.18%; Found C, 53.06%; H, 8.02%; N, 6.09%.

EXAMPLE 13

15 N,N-Dimethyl-N-[3-(hexadecanoyloxy)propyl]-N-[5'-(2',5'-dideoxy)thymidiny] ammonium iodide:

The title compound was prepared in a manner similar to that of the compound of Example 5 from 5'-iodothymidine (0.2 g, 0.57 mmol) and 3-(dimethylamino)propyl hexadecanoate (0.6 g, 1.7 mmol) in acetonitrile (10 mL). Yield 36%; Wt. 0.14 g; very hygroscopic; ¹H NMR (CDCl₃) 0.70-0.78 (t, CH₃ (CH₂)₁₂), 1.11-1.23 (m, CH₃ (CH₂)₁₂), 1.42-1.53 (m, CH₂ CH₂ CO), 1.70-1.75 (s, CH₃ C5 thymine), 2.18-2.35 (t, CH₂ CH₂ CO), 2.28-2.68 (m, H₂ C2'; O CH₂ CH₂ CH₂ N), 3.22-3.42 (s, (CH₃)₂ N), 3.58-3.72 (m, O CH₂ CH₂ N CH₂; H C4'), 4.12-4.30 (m, O CH₂ CH₂ N CH₂), 4.48-4.56 (m, H C3'; C(O)O CH₂), 6.02-6.10 (t, H C1'), 7.50-7.53 (s, H C6 thymine), 10.20-10.25 (s, HN thymine). FAB Mass Spectrum (M)⁺; Calcd. 566.4169 (C₃₁H₅₆O₆N₃); Found 566.4178 (1.60 ppm).

EXAMPLE 14

N,N-Dimethyl-N-3-hydroxypropyl-N- [N⁹- (guanyl)methoxyethyl] ammonium iodide:

The title compound was synthesized in a manner analogous to that of the compound of Example 1 from 9-[(2-iodoethoxy)methyl] guanine (100 mg, 0.32 mmol) and 3-dimethylamino-1-propanol (40 mg, 0.38 mmol) in acetonitrile (10 mL).

EXAMPLE 15


10 Tablet Formulation

<u>Ingredient</u>	<u>mg/tablet</u>
Compound of formula I	50
Starch	50
Mannitol	75
15 Magnesium stearate	2
Stearic acid	5


The compound of formula I, a portion of the starch and the lactose are combined and wet granulated with starch paste. The wet granulation is placed on trays and allowed to dry overnight at a temperature of 45 degrees Centigrade. The dried granulation is comminuted in a comminutor to a particle size of approximately 20 mesh. Magnesium stearate, stearic acid and the balance of the starch are added and the entire mix blended prior to compression on a suitable tablet press. The tablets are compressed at a weight of 232 mg. using a 11/32" punch with a hardness of 4 kg.

WHAT IS CLAIMED IS:

- 1 1. A compound of the Formulae I




- 3 wherein R is a group of the formula




- 7 wherein R_1 is one or two lower alkyl groups with the
8 proviso that when two lower alkyl groups are present,
9 then the nitrogen atom is quaternized; R_2 is hydrogen or
10 an alkanoyl group of 2-20 carbon atoms; n is 2-6; or

- 11 R is a substituted furanyl group of the formula



- 15 wherein n, R_1 and R_2 are as hereinbefore defined; and the
16 wavy lines indicate either stereochemical configuration;
17 R' and R'' are independently hydrogen, halogen or a lower
18 alkyl, lower alkenyl, lower alkynyl, or aralkyl group;
19 R''' is hydrogen, halogen, alkylthio, amino, acylamino
20 carbamyl or azide; and the pharmaceutically acceptable
21 salts thereof.

1 2. A compound according to Claim 1 wherein R is a group
2 of the formula



6 wherein n is 2-6;

7 R_1 is one or two lower alkyl groups with the
8 proviso that when two lower alkyl groups are present,
9 then the nitrogen atom is quaternized;

10 R_2 is hydrogen or an alkanoyl group of 2-20 carbon
11 atoms; and their pharmaceutically acceptable salts.

1 3. The compound according to Claim 2 which is N,N-
2 dimethyl-N-2-(hexadecanoyloxy)ethyl-N-[N¹-(5-methyl-2,4-
3 dioxypyrimidinyl)methoxyethyl]ammonium iodide, or another
4 pharmaceutically acceptable salt thereof.

1 4. The compound according to Claim 2 which is N,N-
2 dimethyl-N-2-(octanoyloxy)ethyl-N-[N¹-(5-methyl-2,4-
3 dioxypyrimidinyl)methoxyethyl]ammonium iodide, or another
4 pharmaceutically acceptable salt thereof.

1 5. The compound according to Claim 2 which is N-methyl-
2 N-(2-hydroxyethyl)-N-[N¹-(5-methyl-2,4-
3 dioxypyrimidinyl)methoxyethyl]amine, or pharmaceutically
4 acceptable salt thereof.


1 6. The compound according to Claim 2 which is N,N-
2 dimethyl-N-(2,3-dihydroxypropyl)-N-[N¹-(5-methyl-2,4-
3 dioxypyrimidinyl)methoxyethyl]ammonium iodide, or another
4 pharmaceutically acceptable salt thereof.

1 7. The compound according to Claim 2 which is N,N-
2 dimethyl-N-(3-hydroxypropyl)-N-[N¹-(5-methyl-2,4-
3 dioxypyrimidinyl)methoxyethyl]ammonium iodide, or another
4 pharmaceutically acceptable salt thereof.

1 8. The compound according to Claim 2 which is N,N-
 2 dimethyl-N-(2-hydroxyethyl)-N-[N'-(5-methyl-2,4-
 3 dioxypyrimidinyl)methoxyethyl]ammonium iodide, or another
 4 pharmaceutically acceptable salt thereof.

1 9. The compound according to Claim 2 which is N,N-
 2 dimethyl-N-3-(hexadecanoyloxy)propyl)-N-[N'-(5-methyl-
 3 2,4-dioxypyrimidinyl)methoxyethyl]ammonium iodide, or
 4 another pharmaceutically acceptable salt thereof.

1 10. A compound according to Claim 1 wherein R is a group
 2 of the formula



6 wherein n is 2-6, and the wavy lines indicate either
 7 stereochemical configuration;

8 R_1 is one or two lower alkyl groups with the
 9 proviso that when two lower alkyl groups are present,
 10 then the nitrogen atom is quaternized;

11 R_2 is hydrogen or an alkanoyl group of 1-20 carbon
 12 atoms; and their pharmaceutically acceptable salts.

1 11. The compound according to Claim 10 which is N,N-
 2 dimethyl-N-2-hydroxyethyl-N-[5'-(2',5'-
 3 dideoxythymidinyl)]ammonium iodide, or another
 4 pharmaceutically acceptable salt thereof.

1 12. The compound according to Claim 10 which is N-
 2 methyl-N-hydroxyethyl-[5'-(2',5'-
 3 dideoxy)ethymidinyl]amine or a pharmaceutically
 4 acceptable salt thereof.

1 13. The compound according to Claim 10 which is N,N-
 2 dimethyl-N-3-hydroxypropyl-N-[5'-(2',5'-


3 dideoxythymidnyl)] ammonium iodide or another
4 pharmaceutically salt thereof.

1 14. The compound according to Claim 10 which is N,N-
2 dimethyl-N-[2-(octanoyl)ethyl]-N-[5'-(2',5'-
3 dideoxy)thymidiny] ammonium iodide or another
4 pharmaceutically acceptable salt thereof.


1 15. The compound according to Claim 10 which is N,N-
2 dimethyl-N-[2-(hexadecanoyloxy)ethyl]-N-[5'-(2'5'-
3 dideoxy)thymidinyl] ammonium iodide or another
4 pharmaceutically acceptable salt thereof.

1 16. The compound according to Claim 10 which is N,N-
2 dimethyl-N-[3-(hexadecanoyloxy)propyl]-N-[5'-(2'5'-
3 dideoxy)thymidinyl] ammonium iodide or another
4 pharmaceutically acceptable salt thereof.

1 17. A pharmaceutical composition which comprises a
2 cytokine inhibitory amount of a compound of the Formula I




4 wherein R is a group of the formula




8 wherein R_1 is one or two lower alkyl groups with the
9 proviso that when two lower alkyl groups are present,
10 then the nitrogen atom is quaternized; R_2 is hydrogen or
11 an alkanoyl group of 2-20 carbon atoms; n is 2-6; or

12 R is a substituted furanyl group of the formula



16 wherein n, R₁ and R₂ are as hereinbefore defined; and the
17 wavy lines indicate either stereochemical configuration;
18 R' and R'' are independently hydrogen, halogen or a lower
19 alkyl, lower alkenyl, lower alkynyl, or aralkyl group;
20 R''' is hydrogen, halogen, alkylthio, amino, acylamino
21 carbamyl or azide; and the pharmaceutically acceptable
22 salts thereof; together with a pharmaceutically
23 acceptable carrier therefor.

1 18. A composition according to Claim 17 wherein R is a
2 group of the formula



6 wherein n is 2-6;

7 R₁ is one or two lower alkyl groups with the
8 proviso that when two lower alkyl groups are present,
9 then the nitrogen atom is quaternized;

10 R₂ is hydrogen or an alkanoyl group of 2-20 carbon
11 atoms; and their pharmaceutically acceptable salts.

1 19. The composition according to Claim 18 which is N,N-
2 dimethyl-N-2-(hexadecanoyloxy)ethyl-N-[N¹-(5-methyl-2,4-
3 dioxypyrimidinyl)methoxyethyl]ammonium iodide, or another
4 pharmaceutically acceptable salt thereof.

1 20. The composition according to Claim 18 which is N,N-
2 dimethyl-N-2-(octanoyloxy)ethyl-N-[N¹-(5-methyl-2,4-
3 dioxypyrimidinyl)methoxyethyl]ammonium iodide, or another
4 pharmaceutically acceptable salt thereof.

1 21. The composition according to Claim 18 which is N-
 2 methyl-N-(2-hydroxyethyl)-N-[N¹-(5-methyl-2,4-
 3 dioxopyrimidinyl)methoxyethyl]amine, or another
 4 pharmaceutically acceptable salt thereof.


1 22. The composition according to Claim 18 which is N,N-
 2 dimethyl-N-(2,3-dihydroxypropyl)-N-[N¹-(5-methyl-2,4-
 3 dioxopyrimidinyl)methoxyethyl]ammonium iodide, or another
 4 pharmaceutically acceptable salt thereof.

1 23. The composition according to Claim 18 which is N,N-
 2 dimethyl-N-(3-hydroxypropyl)-N-N¹-(5-methyl-2,4-
 3 dioxopyrimidinyl)methoxyethyl]ammonium iodide, or another
 4 pharmaceutically acceptable salt thereof.

1 24. The composition according to Claim 18 which is N,N-
 2 dimethyl-N-(2-hydroxyethyl)-N-[N¹-(5-methyl-2,4-
 3 dioxopyrimidinyl)methoxyethyl]ammonium iodide, or another
 4 pharmaceutically acceptable salt thereof.

1 25. The composition according to Claim 17 which is N,N-
 2 dimethyl-N-3-(hexadecanoyloxy)propyl)-N-
 3 dioxopyrimidinyl)methoxyethyl]ammonium iodide, or another
 4 pharmaceutically acceptable salt thereof.

1 26. A composition according to Claim 17 wherein R is a
 2 group of the formula



6 wherein n is 2-6; and the wavy lines indicate either
 7 stereochemical configuration;

8 R_1 is one or two lower alkyl groups with the
 9 proviso that when two lower alkyl groups are present,
 10 then the nitrogen atom is quaternized;

11 R₂ is hydrogen or an alkanoyl group of 2-20 carbon
12 atoms; and their pharmaceutically acceptable salts.

1 27. The composition according to Claim 26 which is
2 N,N-dimethyl-N-2-hydroxyethyl-N-[5'-(5'-
3 deoxythymidinyl)]ammonium iodide, or another
4 pharmaceutically acceptable salt thereof.

1 28. The composition according to Claim 26 which is
2 N-methyl-N-hydroxyethyl-[5'-(2',5'-
3 dideoxy)ethymidinyl]amine or a pharmaceutically
4 acceptable salt thereof.

1 29. The composition according to Claim 2 which is
2 N,N-dimethyl-N-3-hydroxypropyl-N-[5'-(5'-
3 deoxythymidinyl)]ammonium iodide or another
4 pharmaceutically salt thereof.

1 30. The composition according to Claim 26 which is
2 N,N-dimethyl-N-[2-(octanoyl)ethyl]-N-[5'-(2',5'-
3 dideoxy)thymidinyl]ammonium iodide or another
4 pharmaceutically acceptable salt thereof.


1 31. The composition according to Claim 26 which is
2 N,N-dimethyl-N-[2-(hexadecanoyloxy)ethyl]-N-[5'-(2'5'-
3 dideoxy)thymidinyl]ammonium iodide or another
4 pharmaceutically acceptable salt thereof.

1 32. The composition according to Claim 26 which is
2 N,N-dimethyl-N-[3-(hexadecanoyloxy)propyl]-N-[5'-(2'5'-
3 dideoxy)thymidinyl]ammonium iodide or another
4 pharmaceutically acceptable salt thereof.


1 33. A method for inhibiting inflammatory cytokines which
2 comprises administration to a mammal in need of such
3 therapy of a cytokine inhibitory amount of a compound of
4 the Formula I

47

5



(I)




6 R is a group of the formula

7

8

9




10 wherein R_1 is one or two lower alkyl groups with the
 11 proviso that when two lower alkyl groups are present,
 12 then the nitrogen atom is quaternized; R_2 is hydrogen or
 13 an alkanoyl group of 2-20 carbon atoms; n is 2-6; or

14 R is a substituted furanyl group of the formula

15

16

17




18 wherein R_1 and R_2 are as hereinbefore defined; and the
 19 wavy lines indicate either stereochemical configuration;
 20 R' and R'' are independently hydrogen, halogen or a lower
 21 alkyl, lower alkenyl, lower alkynyl, or aralkyl group;
 22 R''' is hydrogen, halogen, alkylthio, amino, acylamino
 23 carbamyl or azide; and the pharmaceutically acceptable
 24 salts thereof.

1 34. A method according to Claim 33 wherein R is a group
 2 of the formula

3

4

5

6 wherein n is 2-6;

7 R_1 is one or two lower alkyl groups with the
 8 proviso that when two lower alkyl groups are present,
 9 then the nitrogen atom is quaternized;

10 R₂ is hydrogen or an alkanoyl group of 2-20 carbon
11 atoms; and their pharmaceutically acceptable salts.

1 35. The method according to Claim 33 which is N,N-
2 dimethyl-N-2-(hexadecanoyloxy)ethyl-N-[N¹-(5-methyl-2,4-
3 dioxypyrimidinyl)methoxyethyl]ammonium iodide, or another
4 pharmaceutically acceptable salt thereof.

1 36. The method according to Claim 34 which is N,N-
2 dimethyl-N-2-(octanoyloxy)ethyl-N-[N¹-(5-methyl-2,4-
3 dioxypyrimidinyl)methoxyethyl]ammonium iodide, or another
4 pharmaceutically acceptable salt thereof.

1 37. The method according to Claim 34 which is N-methyl-
2 N-(2-hydroxyethyl)-N-[N¹-(5-methyl-2,4-
3 dioxypyrimidinyl)methoxyethyl]amine, or another
4 pharmaceutically acceptable salt thereof.


1 38. The method according to Claim 34 which is N,N-
2 dimethyl-N-(2,3-dihydroxypropyl)-N-[N₁-(5-methyl-2,4-
3 dioxypyrimidinyl)methoxyethyl]ammonium iodide, or another
4 pharmaceutically acceptable salt thereof.

1 39. The method according to Claim 34 which is N,N-
2 dimethyl-N-(3-hydroxypropyl)-N-[N₁-(5-methyl-2,4-
3 dioxypyrimidinyl)methoxyethyl]ammonium iodide, or another
4 pharmaceutically acceptable salt thereof.

1 40. The method according to Claim 34 which is N,N-
2 dimethyl-N-(2-hydroxyethyl)-N-[N¹-(5-methyl-2,4)-
3 dioxypyrimidinyl)methoxyethyl]ammonium iodide, or another
4 pharmaceutically acceptable salt thereof.

1 41. The method according to Claim 34 which is N,N-
2 dimethyl-N-3-(hexadecanoyloxy)propyl)-N-
3 dioxypyrimidinyl)methoxyethyl]ammonium iodide, or another
4 pharmaceutically acceptable salt thereof.

1 42. A method according to Claim 33 wherein R is a group
2 of the formula



6 wherein n is 2-6, and the wavy lines indicate either
7 stereochemical configuration;

8 R_1 is one or two lower alkyl groups with the
9 proviso that when two lower alkyl groups are present,
10 then the nitrogen atom is quaternized;

11 R_2 is hydrogen or an alkanoyl group of 1-20 carbon
12 atoms; and their pharmaceutically acceptable salts.

1 43. The method according to Claim 42 which is N,N-
2 dimethyl-N-2-hydroxyethyl-N-[5'-(5'-
3 deoxythymidinyl)]ammonium iodide, or another
4 pharmaceutically acceptable salt thereof.

1 44. The method according to Claim 42 which is N-methyl-
2 N-hydroxyethyl-[5'-(2',5'-dideoxy)ethymidinyl]amine or a
3 pharmaceutically acceptable salt thereof.

1 45. The method according to Claim 42 which is N,N-
2 dimethyl-N-3-hydroxypropyl-N-[5'-(5'-
3 deoxythymidinyl)]ammonium iodide or another
4 pharmaceutically salt thereof.

1 46. The method according to Claim 42 which is N,N-
2 dimethyl-N-[2-(octanoyl)ethyl]-N-[5'-(2',5'-
3 dideoxy)thymidinyl]ammonium iodide or another
4 pharmaceutically acceptable salt thereof.

1 47. The method according to Claim 42 which is N,N-
2 dimethyl-N-[2-(hexadecanoyloxyl)ethyl]-N-[5'-(2'5'-
3 dideoxy)thymidinyl]ammonium iodide or another
4 pharmaceutically acceptable salt thereof.

1 48. The method according to Claim 42 which is N,N-
2 dimethyl-N-[3-(hexadecanoyloxy)propyl]-N-[5'-(2'5'-
3 dideoxy)thymidinyl]ammonium iodide or another
4 pharmaceutically acceptable salt thereof.

1 49. The method according to Claim 33 wherein the mammal
2 under treatment is afflicted with septic shock.

1 50. The method according to Claim 33 wherein the mammal
2 under treatment is afflicted with cachexia.

1 51. The method according to Claim 33 wherein the mammal
2 under treatment is afflicted with rheumatoid arthritis.

1 52. The method according to Claim 33 wherein the mammal
2 under treatment is afflicted with inflammatory bowel
3 disease.

1 53. The method according to Claim 33 wherein the mammal
2 under treatment is afflicted with multiple sclerosis.

1 54. The method according to Claim 33 wherein the mammal
2 under treatment is afflicted with AIDS.

1 55. The method according to Claim 33 wherein the mammal
2 under treatment is afflicted with Alzheimer's Disease.

1 56. The method according to Claim 33 wherein the
2 inflammatory cytokine being inhibited is tumor necrosis
3 factor (TNF).

1 57. The method according to Claim 56 wherein the mammal
2 under treatment is afflicted with septic shock.

1 58. The method according to Claim 56 wherein the mammal
2 under treatment is afflicted with cachexia.

1 59. The method according to Claim 56 wherein the mammal
2 under treatment is afflicted with rheumatoid arthritis.

1 60. The method according to Claim 56 wherein the mammal
2 under treatment is afflicted with inflammatory bowel
3 disease.

1 61. The method according to Claim 56 wherein the mammal
2 under treatment is afflicted with multiple sclerosis.

1 62. The method according to Claim 56 wherein the mammal
2 under treatment is afflicted with AIDS.

1 63. The method according to Claim 56 wherein the mammal
2 under treatment is afflicted with Alzheimer's Disease.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/07896

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07H19/06 C07H19/16 A61K31/70 C07D239/54 C07D473/00
A61K31/505 A61K31/52

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07D C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,92 17186 (WISCONSIN ALUMNI RESEARCH FOUNDATION) 15 October 1992 see page 2, line 11 - page 3, line 21 ---	1,17,33
A	JOURNAL OF IMMUNOLOGY, vol. 151, no. 1, 1 July 1993 pages 389-396, PARMELY M.J. ET AL 'Adenosine and a Related Carbocyclic Nucleoside Analogue Selectively Inhibit Tumor Necrosis Factor-alpha Production and Protect Mice against Endotoxin Challenge' see the whole document --- -/--	1,17,33

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

3 November 1995

Date of mailing of the international search report

15.11.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Day, G

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 95/07896

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LIEBIGS ANNALEN DER CHEMIE, no. 5, 1985 pages 1036-1040, KOLB M. AND BARTH J. 'Synthesis of 5'-[(3-Aminooxypropyl)amino]-5'-deoxyadeno sine' see page 1037 ---	1
P,A	CIRCULATORY SHOCK, vol. 44, November 1994 pages 97-103, LEE J.C. ET AL 'Low-Molecular-Weight TNF Biosynthesis Inhibitors: Strategies and Prospectives' see the whole document -----	1,17,33

Information on patent family members

PLI/US 95/07896

Form PCT/ISA/210 (patent family annex) (July 1992)